Preclinical evaluation
A phase of drug development in which studies are conducted prior to clinical testing in human subjects. These studies test safety and efficacy in animals.
 Inhibitory activity
The degree to which a compound binds to a protein thought to cause a specific disease indication and inhibits the function of the protein. Usually expressed in terms of the concentration of the compound.
 Drug candidate compound design technology
Optimum Packing of Molecular Fragments (OPMF), a software module developed by Fujitsu that designs small molecule compounds that bind to the functional site of proteins that are believed to cause specific disease indications and inhibit the activity of the proteins.
 High-precision activity prediction technology
Software developed by Fujitsu Laboratories comprised of MAPLE CAFEE, a module that, based on molecular dynamics calculations, predicts the inhibitory activity of drug candidate compounds with a high level of precision that is equivalent to that of biochemical assays, and Force Field Formulator for Organic Molecules (FF-FOM), a module that generates highly detailed parameters for the force fields between atoms.
Fujitsu is the leading Japanese information and communication technology (ICT) company offering a full range of technology products, solutions and services. Approximately 162,000 Fujitsu people support customers in more than 100 countries. We use our experience and the power of ICT to shape the future of society with our customers. Fujitsu Limited (TSE: 6702) reported consolidated revenues of 4.8 trillion yen (US$46 billion) for the fiscal year ended March 31, 2014. For more information, please see http://www.fujitsu.com.
Kowa is a privately held multinational company headquartered in Nagoya, Japan. Established in 1894, Kowa is actively engaged in various manufacturing and trading activities in the fields of pharmaceuticals, life science, information technology, textiles, machinery and various consumer products. Kowa’s pharmaceutical division is focused on research and development for cardiovascular therapeutics (dyslipidemia, type 2 diabetes, and atherosclerosis), ophthalmology and anti-inflammatory agents.
Global sales of the company's flagship product, pitavastatin (known as LIVALO and LIVAZO in different markets) was over 80 billion yen (US$800 million) in 2013.
For more information, please see http://www.kowa.co.jp/eng/.
All company or product names mentioned herein are trademarks or registered trademarks of their respective owners. Information provided in this press release is accurate at time of publication and is subject to change without advance notice.
Date: 07 August, 2014
City: Tokyo and Nagoya, Japan
Company: Research Center for Advanced Science and Technology, The University of Tokyo, Fujitsu Limited, Kowa Company, Ltd.